128 results about "Psychiatry" patented technology

The application discloses a kind of fusion training method and system for multiple cognitive abilities.The fusion training method includes: obtaining the cognitive evaluation result of user for attention, inhibition and memory;Based on the cognitive evaluation result, obtain the first training parameter related to attention and inhibition;Based on the first training parameter, obtain the second training parameter related to memory;Based on the first training parameter and the second training parameter, configure the cognitive training task of corresponding difficulty level and training duration for user;Push the cognitive training task to user for cognitive training, for simultaneously training the attention, inhibition and memory of user;Obtain the cognitive training data of user, and feedback the current cognitive training result to user.The fusion training method can integrate multidimensional cognitive ability training into one, break the common single cognitive ability training form, and help to improve and transfer the comprehensive ability of user.

The application discloses application of T1R3 agonist sucralose in relieving Alzheimer's disease and related cognitive impairment, and aims at brain glucose metabolism disorder and cognitive decline problem, and the application takes sucralose as the only pharmaceutical active ingredient, corrects brain glucose metabolism disorder through targeting brain astrocyte sweet taste receptor T1R3, and then treats and relieves neurodegenerative diseases. The application is proved by animal experiments that cognitive dysfunction of AD model mice can be improved in a full range of molecular mechanisms, cell functions, tissue metabolisms and whole behavior, and a variety of dosage forms and medication strategies can be selected, and the application has good in-vivo safety and clinical transformation potential.

To provide an agent for treating or preventing amyotrophic lateral sclerosis.SOLUTION: This agent for treating or preventing amyotrophic lateral sclerosis essentially comprises at least one active ingredient selected from the group consisting of cycloserine and terizidone, and salts thereof. The active ingredient may be at least one selected from the group consisting of cycloserine and terizidone, and salts thereof. The cycloserine may be D-cycloserine. The cycloserine may be L-cycloserine.SELECTED DRAWING: Figure 8

The present disclosure is directed to compounds of Formula I and their use as TREM2 agonists for treatment and prevention of a neurodegenerative disorder associated with a loss of function of human TREM2. The disclosed TREM2 agonists may be useful for the treatment of Alzheimer's Disease and associated neurological conditions.

This invention discloses a sleep-aid composition that synergistically regulates sleep rhythm with 5-HTP and L-theanine, relating to the fields of biomedicine and health food technology. This invention effectively regulates sleep rhythm through the synergistic effect of 5-hydroxytryptophan, L-theanine, and γ-aminobutyric acid (GABA), helping users improve sleep quality. 5-HTP, as a precursor to serotonin, helps increase serotonin levels, which are then converted into melatonin, regulating the sleep cycle. L-theanine promotes the release of alpha brain waves, helping to relax the mind and body and reduce anxiety. GABA, as an inhibitory neurotransmitter, effectively relieves tension and promotes deep sleep. The synergistic effect of these three components provides users with more comprehensive and effective sleep support.

Prodrugs of itaconic acid and 1- and 4-methyl itaconic acid and their use for treating a disease, disorder, or condition associated with inflammation are disclosed.

The present disclosure provides methods of treating, preventing, or delaying the onset of a late-onset neurodegenerative disease, e.g., Niemann-Pick type C, or a symptom thereof in a subject in need thereof, comprising administering a therapeutically effective amount of acetyl-leucine to the subject, wherein the subject is heterozygous NPC1 gene mutation carrier.

The present disclosure is directed to methods of producing a predictive model or human avatars for assessing Central Nervous System (CNS) disorders using organoids, optionally with artificial intelligence (Al).

The invention relates to an active agent increasing the activity of α-carbonic anhydrase (hCA) enzymes, having the potential for use in the treatment of Alzheimer's and certain neurodegenerative disorders.

Methods and composition are provided for treatment of various disorders associated with decreased neurogenesis, including age-related neurodegeneration, such as Alzheimer' s disease.

The invention relates to certain chromanol, quinone or hydroquinone compounds and derivatives thereof for treatment of Alzheimer's disease and / or for improving memory function and / or reducing plaque load. Specifically, the present invention relates to chromanol compounds chosen from (6-hydroxy-2,5,7,8-tetramethylchroman-2yl)(piperazin-1-5 yl)methanone, ((S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2- carboxamide hydrochloride and S-(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(4-(2- hydroxyethyl)piperazin-1-yl)methanone, and pharmaceutically acceptable salts thereof.

A method of reducing fear memory in a mammal comprising the step of inhibiting or reducing cAMP signaling in the mammal. The cAMP signaling can be reduced using an adenylyl cyclase 1 (AC1) inhibitor or using a phosphodiesterase, such as a cAMP-specific phosphodiesterase, such as PDE4.

The application discloses application of SCAMP5 in treatment of autism spectrum disorder. The application research proves that, compared with a CON group, VPA-induced ASD rats have significant neurotransmitter release disorder and synapse signal path abnormality in hippocampus, overexpression of SCAMP5 protein can improve abnormal release of Glu, abnormal expression of scaffold protein Homer1b / c and downstream protein IP3R, and meanwhile, can relieve autism-like behaviors, space working memory and synapse development abnormality of ASD rats. The application provides a new target and a new potential drug for treatment of autism spectrum disorder, and provides a new idea for target treatment of ASD by in-depth exploration of potential path in pathogenesis of autism.

To provide a technique to test mild cognitive impairment by olfactometry.SOLUTION: A subject can be diagnosed as having mild cognitive impairment by olfactory tests each using butter-like flavor liquid, toothpaste-like flavor liquid, and Indian ink-like flavor liquid.SELECTED DRAWING: None

The present invention is directed to, in part, compounds and compositions useful for preventing and / or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and / or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and / or a gain-of-function mutation in a gene such as KCNT1 are also provided herein. 20 26 20 50 63 29 J un 2 02 6 A B S T R A C T 2 0 2 6 2 0 5 0 6 3 2 9 J u n 2 0 2 6

The present disclosure provides methods of preventing and / or treating hearing loss in an individual comprising administering to the individual a composition comprising an agent that increases the expression and / or activity of a Pou4f3 protein. The present disclosure also provides methods of preventing and / or treating a vestibular disorder in an individual comprising administering to the individual a composition comprising an agent that increases the expression and / or activity of a Pou4f3 protein.

The present invention relates to a novel microRNA for in vitro early diagnosis of mild cognitive impairment and Alzheimer's dementia, and a convergence diagnostic cartridge and diagnostic device using same. The novel miRNA of SEQ ID NO: 1 obtained by molecular analysis exhibits differences in expression levels in the plasma of a normal group, a mild cognitive impairment patient group, and an Alzheimer's dementia patient group, and has the effect of reducing the expression levels of mild cognitive impairment- and Alzheimer's dementia-related proteins. Therefore, by using a novel miRNA present in plasma as a molecular diagnostic index in a non-invasive manner, the present invention enables not only early diagnosis of Alzheimer's dementia but also screening for mild cognitive impairment and Alzheimer's dementia.

The present disclosure relates to a composition for preventing or treating brain-related inflammation disease or neurodegenerative disease, comprising entrectinib. The composition exhibits an effect of inhibiting brain-related inflammation and alleviating memory impairment, and thus may be usefully used for the prevention, alleviation, or treatment of brain-related inflammation disease, neurodegenerative disease, memory impairment, etc.

The present invention provides a long-acting K-opioid receptor agonist. This long-acting K-opioid receptor agonist is used to alleviate moderate to severe itching in patients and for postoperative pain relief.

The present invention discloses a sleep-aid composition for synergistically regulating the sleep rhythm with 5-HTP and L-theanine, relating to the technical field of biomedicine and health foods. Through the synergistic action of 5-hydroxytryptophan, L-theanine, and gamma-aminobutyric acid, the present invention effectively regulates the sleep rhythm and helps users improve sleep quality. As a precursor of serotonin, 5-HTP helps increase the serotonin level and is then converted into melatonin to regulate the sleep cycle. L-theanine promotes the release of alpha brain waves to help relax the body and mind and reduce anxiety. As an inhibitory neurotransmitter, GABA can effectively relieve tension and promote deep sleep. The three components act synergistically to provide users with more comprehensive and more effective sleep support.

Provided are methods of treating a Primary Mitochondrial Disorder (PMD) or Mitochondrial DNA Depletion Syndrome (MDDS) in a subject in need thereof comprising: administering a therapeutically effective amount of a compound listed in Table 1, Table 2, Table 3, Table 4, or Table 5. The subject may have one or more mutations or deletions in the DNA polymerase γ gene (POLG).

The present invention relates to a cyclic derivative, a preparation method therefor and the use thereof. The cyclic derivative can be used as a muscarinic acetylcholine receptor agonist and / or a Sigma receptor agonist, or can be used for treating schizophrenia, Parkinson's disease, Alzheimer's disease, depression and other neuropsychiatric diseases.

To provide a cognitive function estimation device capable of estimating a cognitive function of a subject easily and accurately.SOLUTION: A cognitive function estimation device includes a gait information acquisition part, an estimation parameter calculation part, and a determination part. The gait information acquisition part is configured to acquire gait information acquired by an inertial sensor attached to the foot of a subject, the gait information including at least one of information on acceleration of the foot of the walking subject and information on an angular speed. The estimation parameter calculation part is configured to calculate cognitive function estimation parameters on the basis of the gait information. The determination part is configured to determine presence or absence of mild cognitive impairment (MCI) of the subject on the basis of the cognitive function estimation parameters.SELECTED DRAWING: Figure 1

This invention relates to the field of signal recognition technology, specifically to a method and system for recognizing neurophysiological signal patterns in the language development of premature infants. The method includes acquiring initial neurophysiological response information and auditory stimulation parameters collected during auditory stimulation of the premature infant; extracting language development feature information; determining the neural response state of the premature infant to the current stimulus based on the language development feature information; adjusting the auditory stimulation parameters according to the neural response state to obtain adjusted auditory stimulation parameters; using the adjusted auditory stimulation parameters to provide further auditory stimulation to the premature infant, determining the adjusted neurophysiological response information; and recognizing the neural development of language in the premature infant based on the adjusted neurophysiological response information to obtain the neural recognition result of language development in the premature infant. The purpose of this invention is to solve the problem of inaccurate assessments due to biases in the existing technology for evaluating the language abilities of premature infants.

The present disclosure relates generally to compounds, their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.